Research Summary

Research Summary
I am a medical oncologist specializing in hematologic malignancy, with a particular emphasis on Hodgkin’s lymphoma, Non-Hodgkin’s lymphoma, and skin lymphomas. I have conducted numerous clinical trials in each of these areas. My laboratory research focuses on developing patient-derived murine models for T cell lymphomas, as well as conducting pre-clinical studies of novel agents.

Physician Biography
Dr. Ai specializes in the research and treatment of non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, cutaneous lymphoma and bone marrow transplantation. She cares for patients at the UCSF Helen Diller Family Comprehensive Cancer Center and Department of Dermatology. She serves as a co-director of the UCSF Cutaneous Lymphoma Program. Dr. Ai graduated top of her class from Beijing University in cell biology and genetics. She earned a Ph.D. in microbiology and immunology, as well as her M.D. degree from Stanford University School of Medicine. After a residency in medicine at UCSF and an oncology fellowship at Stanford University, Dr. Ai joined the faculty at UCSF in 2007. She serves on both the Hodgkin’s lymphoma and T cell lymphoma committees, as well as the International Program of the National Comprehensive Cancer Care Network (NCCN). Dr. Ai’s research focuses on novel approaches to lymphoma treatment, especially targeted agents for T cell lymphomas. She has published widely in medical and scientific journals.

Education

Beijing University, China, Bsc, 1984-1987, Cell Biology and Genetics
Columbia University Medical School, New York, 1987-1989, Microbiology & Immunology
Stanford University School of Medicine, California, PhD, 1989-1995, Microbiology & Immunology
Stanford University School of Medicine, California, MD, 1996-2000, Medicine

Honors & Awards

  • 1997
    Beckman Scholar, Stanford University
  • 1998
    Dean's Scholar, Stanford University
  • 2005
    Young Investigator Award by American Society of Clinical Oncology (ASCO)
  • 2005
    Lisa Beth Fishman Memorial Fellow of Lymphoma Research Foundation (2005-2007)
  • 2006
    Travel Award by American Society of Hematology (ASH)
  • 2006
    Brigid G. Leventhal Scholar Awards by American Association for Cancer Research (AACR)

Selected Publications

  1. Wu CH, Wang L, Yang CY, Wen KW, Hinds B, Gill R, McCormick F, Moasser M, Pincus L, Ai WZ. Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft models. Blood Adv. 2022 Apr 12; 6(7):2290-2302.  View on PubMed
  2. Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Armand P, Bello CM, Benitez CM, Chen W, Dabaja B, Daly ME, Gordon LI, Hansen N, Herrera AF, Hochberg EP, Johnston PB, Kaminski MS, Kelsey CR, Kenkre VP, Khan N, Lynch RC, Maddocks K, McConathy J, Metzger M, Morgan D, Mulroney C, Pullarkat ST, Rabinovitch R, Rosenspire KC, Seropian S, Tao R, Torka P, Winter JN, Yahalom J, Yang JC, Burns JL, Campbell M, Sundar H. NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022. J Natl Compr Canc Netw. 2022 04; 20(4):322-334.  View on PubMed
  3. Kennedy VE, Huang CY, Kaplan LD, Andreadis C, Ai WZ, Olin RL. Geriatric assessment in adults age 50 years and older undergoing autologous hematopoietic cell transplantation for lymphoma. J Geriatr Oncol. 2022 Mar 04.  View on PubMed
  4. Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Brammer J, Clemens MW, Dogan A, Foss F, Ghione P, Goodman AM, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Jones A, Kallam A, Kim YH, Kumar K, Mehta-Shah N, Olsen EA, Rajguru SA, Rozati S, Said J, Shaver A, Shea L, Shinohara MM, Sokol L, Torres-Cabala C, Wilcox R, Wu P, Zain J, Dwyer M, Sundar H. T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 03; 20(3):285-308.  View on PubMed
  5. Hess B, Townsend W, Ai W, Stathis A, Solh M, Alderuccio JP, Ungar D, Liao S, Liao L, Khouri L, Zhang X, Boni J. Efficacy and Safety Exposure-Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin Lymphoma. AAPS J. 2021 12 10; 24(1):11.  View on PubMed
  6. Halwani AS, Panizo C, Isufi I, Herrera AF, Okada CY, Cull EH, Kis B, Chaves JM, Bartlett NL, Ai W, de la Cruz-Merino L, Bryan LJ, Houot R, Linton K, Briones J, Chau I, von Keudell GR, Lu H, Yakovich A, Chen M, Meulen Jh T, Yurasov S, Hsu FJ, Flowers CR. Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma. Leuk Lymphoma. 2022 Apr; 63(4):821-833.  View on PubMed
  7. Caimi PF, Ardeshna KM, Reid E, Ai W, Lunning M, Zain J, Solh M, Kahl BS, Hamadani M. The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy. Clin Lymphoma Myeloma Leuk. 2022 05; 22(5):e335-e339.  View on PubMed
  8. Olsen EA, Whittaker S, Willemze R, Pinter-Brown L, Foss FM, Geskin LJ, Schwartz LH, Horwitz SM, Guitart J, Zic J, Kim YH, Wood GS, Duvic M, Ai WZ, Girardi M, Gru A, Guenova E, Hodak E, Hoppe RT, Kempf W, Kim EJ, Lechowicz MJ, Ortiz-Romero PL, Papadavid E, Quaglino P, Pittelkow MR, Prince HM, Sanches JA, Sugaya M, Vermeer MH, Zain J, Knobler R, Stadler R, Bagot M, Scarisbrick JJ. Primary Cutaneous Lymphoma: Recommendations for Clinical Trial Design and Staging Update from the ISCL, USCLC, and EORTC. Blood. 2021 Nov 10.  View on PubMed
  9. Fakhri B, Ai W. Current and emerging treatment options in primary mediastinal B-cell lymphoma. Ther Adv Hematol. 2021; 12:20406207211048959.  View on PubMed
  10. Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, Kahl BS, Radford J, Solh M, Stathis A, Zinzani PL, Havenith K, Feingold J, He S, Qin Y, Ungar D, Zhang X, Carlo-Stella C. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021 06; 22(6):790-800.  View on PubMed
  11. Huang LW, Sun D, Link TM, Lang T, Ai W, Kaplan LD, Steinman MA, Andreadis C. High incidence of fractures after R-CHOP-like chemotherapy for aggressive B-cell non-Hodgkin lymphomas. Support Care Cancer. 2021 Sep; 29(9):5399-5408.  View on PubMed
  12. Kennedy VE, Ruiz-Cordero R, Jangam D, Wen KW, Dunavin N, Ohgami RS, Bhargava P, Ai W, Fakhri B. A Case of EBV-Negative Aggressive NK-cell Leukemia: Use of Next-Generation Sequencing in Demystifying a Diagnostic Dilemma and Guiding Clinical Care. Clin Lymphoma Myeloma Leuk. 2021 07; 21(7):e583-e587.  View on PubMed
  13. Charli-Joseph Y, Kashani-Sabet M, McCalmont TH, Kornak J, Allen I, Ai WZ, LeBoit PE, Pincus LB. Association of a Proposed New Staging System for Folliculotropic Mycosis Fungoides With Prognostic Variables in a US Cohort. JAMA Dermatol. 2021 02 01; 157(2):157-165.  View on PubMed
  14. Kambhampati S, Fakhri B, Ai WZ, Kaplan LD, Tuscano JM, Wieduwilt MJ, Sudhindra A, Cavallone E, Reiner J, Aoun C, Castillo M, Martinelli M, Ta T, Le D, Padilla M, Crawford E, Andreadis CB. Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial. Clin Lymphoma Myeloma Leuk. 2021 03; 21(3):139-146.  View on PubMed
  15. Kambhampati S, Hunter B, Varnavski A, Fakhri B, Kaplan L, Ai WZ, Pampaloni M, Huang CY, Martin T, Damon L, Andreadis CB. Ofatumumab, Etoposide, and Cytarabine Intensive Mobilization Regimen in Patients with High-risk Relapsed/Refractory Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2021 04; 21(4):246-256.e2.  View on PubMed
  16. Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Clemens MW, Dogan A, Goodman AM, Goyal G, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Jones A, Kim YH, Mehta-Shah N, Olsen EA, Pro B, Rajguru SA, Rozati S, Said J, Shaver A, Shustov A, Sokol L, Torka P, Torres-Cabala C, Wilcox R, William BM, Zain J, Dwyer MA, Sundar H. NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021. J Natl Compr Canc Netw. 2020 11 02; 18(11):1460-1467.  View on PubMed
  17. Nawas MT, Sheng Y, Huang CY, Andreadis C, Martin TG, Wolf JL, Ai WZ, Kaplan LD, Mannis GN, Logan AC, Damon LE, Olin RL. Serial comprehensive geriatric and quality of life assessments in adults age ≥ 50 years undergoing autologous hematopoietic cell transplantation. J Geriatr Oncol. 2021 05; 12(4):531-539.  View on PubMed
  18. Wang L, Malik A, Roop PS, Cheng LK, Paskaranandavadivel N, Ai W. Design of a closed-loop gastric pacemaker for modulating dysrhythmic conduction patterns via extracellular potentials. Annu Int Conf IEEE Eng Med Biol Soc. 2020 07; 2020:2504-2507.  View on PubMed
  19. Wu CH, Yang CY, Wang L, Gao HX, Rakhshandehroo T, Afghani S, Pincus L, Balassanian R, Rubenstein J, Gill R, Bandyopadhyay S, McCormick F, Moasser M, Ai WZ. Cutaneous T-Cell Lymphoma PDX Drug Screening Platform Identifies Cooperation between Inhibitions of PI3Kα/δ and HDAC. J Invest Dermatol. 2021 02; 141(2):364-373.  View on PubMed
  20. Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Armand P, Bello CM, Benitez CM, Bierman PJ, Boughan KM, Dabaja B, Gordon LI, Hernandez-Ilizaliturri FJ, Herrera AF, Hochberg EP, Huang J, Johnston PB, Kaminski MS, Kenkre VP, Khan N, Lynch RC, Maddocks K, McConathy J, McKinney M, Metzger M, Morgan D, Mulroney C, Rabinovitch R, Rosenspire KC, Seropian S, Tao R, Winter JN, Yahalom J, Burns JL, Ogba N. Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 06; 18(6):755-781.  View on PubMed

Go to UCSF Profiles, powered by CTSI